Aviremia 10 years postdiscontinuation of antiretroviral therapy initiated during primary human immunodeficiency virus-1 infection and association with gag-specific T-cell responses by Kinloch-de Loes, Sabine et al.
B R I E F R E P O R T
Aviremia 10 Years
Postdiscontinuation of Antiretroviral
Therapy Initiated During Primary
Human Immunodeﬁciency Virus-1
Infection and Association With
Gag-Speciﬁc T-Cell Responses
Sabine Kinloch-de Loes,1,2,3,a Lucy Dorrell,4,5,a Hongbing Yang,4,5
Gareth A. D. Hardy,6,7 Sabine Yerly,8 Cristina Cellerai,1,9
Linos Vandekerckhove,10,11 Ward De Spiegelaere,10,11 Eva Malatinkova,10,11
Willie Wee Lee Koh,12,b and Margaret A. Johnson1,2
1Division of Infection and Immunity, Royal Free Campus, University College London,
2Royal Free Hospital, London, 3Department of Immunology, University College
London Medical School, Royal Free Campus, 4Nufﬁeld Department of Medicine,
5Oxford National Institute of Health Research Biomedical Research Centre,
University of Oxford, 6Centre for Immunology and Virology, Imperial College London,
and 7Chelsea and Westminster Hospital, London, United Kingdom; 8Laboratory of
Virology, Geneva University Hospital, and 9Division of Immunology and Allergy,
Department of Medicine, Centre Hospitalier Universitaire Vaudois, Lausanne,
Switzerland; 10HIV Translational Research Unit, Ghent University, 11University
Hospital Ghent, Belgium; and 12Department of Immunology and Molecular
Pathology, University College London Medical School, University College London
Campus, United Kingdom
Combination antiretroviral therapy during primary human
immunodeﬁciency virus-1 infection may enable long-term
drug-free virological control in rare individuals. We describe
a female who maintained aviremia and a normal CD4+/CD8+
T cell ratio for 10 years after stopping therapy, despite a per-
sistent viral reservoir. Cellular immune responses may have
contributed to this outcome.
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Achieving prolonged control of human immunodeﬁciency
virus (HIV)-1 replication after antiretroviral therapy (ART)
interruption is one of the aims of present research efforts to-
wards eradication, to alleviate HIV-1 burden, drug toxicity,
and costs. Initiation of ART during primary HIV-1 infection
(PHI) is associated with reduced size and diversity of viral res-
ervoirs and enhanced immune preservation, relative to chronic
infection. This is reﬂected in prolonged aviremia in a minority
of early treated seroconverters who discontinue ART [1–3].Elu-
cidating the underlying mechanisms may facilitate the develop-
ment of curative therapy. In this study, we describe the favorable
outcome of a woman who initiated ART during a severe acute
retroviral syndrome. She stopped therapy 6 years later and has
since experienced a decade of apparent spontaneous control.
We report the virological and immunological features of this
unusual case.
METHODS
Quantiﬁcation of the Human Immunodeﬁciency Virus-1
Reservoir
Written permission was obtained from the patient for reporting
of her case. The patient was infected with a clade C virus. During
17 years of follow-up, HIV-1 viremia was quantiﬁed with several
validated assays, which included non-B primers in accordance
with laboratory and clinical practice at the time. Low copy vire-
mia was determined as described in Supplementary Methods.
Quantiﬁcation of cell-associated HIV-1 DNA in blood sampled
during 2007–2013 was performed as described previously [4, 5].
Integrated HIV-1 DNA was determined in samples from 2013
onwards by Alu-HIV polymerase chain reaction (PCR), in addi-
tion to quantiﬁcation of total and episomal 2-long terminal
repeat (LTR) circles [6, 7] (Supplementary Methods).
Human Leukocyte Antigen Typing
The patient’s human leukocyte antigen (HLA) type was deter-
mined by ARMS-PCR using sequence-speciﬁc primers as fol-
lows: HLA A*0101, *3001, B*4901, Cw*0701, DRB1 *0804,
DQB1 *0301 (homozygous at HLA-B, Cw, DR, and DQ loci).
Assessment of Human Immunodeﬁciency Virus-1-Speciﬁc
Cellular Immune Responses
T-cell responses to the entire HIV-1 proteome were assessed
initially using pools of clade B 15-mer peptides overlapping
by 11 amino acids and, subsequently, corresponding over-
lapping clade C 18-mers, (NIH AIDS Reagent Program, ﬁnal
concentration 2 µg/mL) in ex vivo interferon (IFN)-γ enzyme-
linked immunospot (ELISPOT) assays, as described previously
[8]. Further details are given in Supplementary Methods.
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Figure 1. CD4 cell count and plasma viral load changes (A), CD4/CD8 cell ratios, and percentage of activated (CD38+) CD8 T cells (B) during primary
infection, antiretroviral therapy, and posttreatment discontinuation are shown. Antiretroviral therapy regimen: nucleoside reverse-transcriptase inhibitors
zidovudine/lamivudine days 12–2121 and tenofovir/lamuvidine days 2122–2289; protease inhibitors indinavir days 12–22, ritonavir (full dose) days 23–203,
and ritonavir/saquinivir days 204–2289. The assays used to quantify human immunodeﬁciency virus (HIV)-1 RNA were as follows, in chronological order:
Roche Amplicor HIV-1 Monitor version 1.0 assay with non-clade B primers added (ﬁrst 2 samples in 1997); Roche COBAS Amplicor HIV-1 Monitor, replaced
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Unfractionated and CD8+-depleted peripheral blood mononu-
clear cells (PBMCs) were also tested in IFN-γ ELISPOT assays
with pools of peptides representing “beneﬁcial regions” that are
preferentially targeted by individuals with reduced viral loads
[9] (Supplementary Table 1).
Ex vivo CD8+ T-cell viral inhibitory activity was determined
using a viral inhibition assay as described previously [8]. Prima-
ry CD4+ T cells were superinfected with laboratory-adapted or
primary virus isolates (Programme EVA Centre for AIDS Re-
agents, National Institute for Biological Standards and Control)
at a multiplicity of infection of 0.01: HIV-1BaL (CCR5-tropic,
clade B), HIV-1IIIB (CXCR4-tropic, clade B), and HIV-1C
(CCR5-tropic, clade C).
RESULTS
Case Report
A 23-year-old woman of Ethiopian origin presented in 1997
with a 3-week history of fever, sore throat, rash, lymphadenop-
athy, myalgia, and arthralgia. Her HIV-1 antibody test was pos-
itive with incomplete reactivity on HIV Western blot. She had
tested HIV-1 seronegative in 1996. Three consecutive CD4+ T-
cell counts were <200 cells/mm3, and her viral load was initially
>750 000 HIV-1 copies (c)/mL. The patient started zidovudine
250 mg twice daily, lamivudine 150 mg twice daily, and indin-
avir 800 mg 3 times a day. The latter was subsequently switched
to ritonavir 600 mg twice daily because of intolerance. She re-
mained viremic (up to 94 400 HIV-1 c/mL) while on treatment
and required intensiﬁcation (twice daily saquinavir 400 mg and
ritonavir 400 mg), which was initiated in May 1998. Suppres-
sion of viremia <50 HIV-1 c/mL was not achieved until approx-
imately 1 year later, but it was sustained for nearly 5 years
thereafter, at which point ART was stopped at the patient’s re-
quest. The pre-ART discontinuation CD4+ T-cell count was
863 cells/mm3 (30%), with a CD4+/CD8+ T-cell ratio of 0.7.
The patient has since remained asymptomatic with undetect-
able viremia, normal CD4+ T-cell counts, and a CD4+/CD8+
T-cell ratio >1 during 10 years of follow-up off ART (Figure 1).
A comprehensive screen for antiviral agents by therapeutic drug
monitoring on a blood sample from 2008 was negative (Delphic
Laboratories Ltd, Merseybio Liverpool, UK). Furthermore, the
frequency of activated (CD38+) CD8+ T cells, which was mea-
sured during 2004–2010, remained within normal limits (3%–
21%) (Figure 1B). Human leukocyte antigen typing revealed
that the patient did not express any HLA class I alleles associ-
ated with long-term control of HIV.
Evidence of a Detectable Human Immunodeﬁciency Virus-1
Reservoir During Posttreatment Control
During the posttreatment period with aviremia, HIV-1 DNA
was detected on 4 occasions: 2004 (not quantiﬁed), 2007,
2013, and 2014. Total HIV-1 DNA was 285, 619, and 149 cop-
ies/106 PBMCs in 2007, 2013, and 2014, respectively. At 15
years of aviremia (2014), integrated HIV-1 DNA and 2-LTR cir-
cles were 134.3 (95% conﬁdence interval [CI], 56.5–304.4) and
3.9 (95% CI, 0–9.15) copies/106 PBMCs, respectively (Fig-
ure 1A). Viremia was undetectable by an ultrasensitive assay
(<2 HIV-1 copies/mL).
CD8+ T Cells Sampled After 10 Years of Posttreatment Control
Suppress Human Immunodeﬁciency Virus-1 Replication In Vitro
Ex vivo CD8+ T cells were tested for their capacity to inhibit the
replication of clade B and C HIV-1 isolates and of endogenous
HIV-1 in autologous CD4+ T cells in vitro. At a CD8+/CD4+
ratio of 1:1, CD8+ T cells demonstrated moderate antiviral ac-
tivity against clade-matched (C, 73.5%) and mismatched (IIIB,
73.3%; BaL, 49%) virus isolates (Figure 1C and D). Efﬁcient
suppression of the clade C isolate was also observed at a lower
CD8+/CD4+ T-cell ratio (1:10%–59% vs 30% for IIIB and 22%
for BaL). Antiviral activity against the patient’s endogenous
virus was equivalent to HIV-1C at both CD8+/CD4+ T cell ra-
tios (70.5% and 52.3% for 1:1 and 1:10 ratios, respectively) (Fig-
ure 1C and D).
Broad CD4+ T-Cell Responses Target Vulnerable Regions Within
Gag
Interferon-γ-secreting CD8+ and CD4+ T cells were predomi-
nantly targeted to 14 regions within HIV-1 Gag, Pol, and Nef
(Figure 1E, Supplementary Figure 1A–C). T-cell responses
were also targeted to 7 vulnerable (beneﬁcial) regions within
the clade B and C viral proteomes (Supplementary Table 1)
and were predominantly CD4+ T cell-mediated (Figure 1E
and 1F, Supplementary Figure 1D).
Figure 1 continued. by version 1.5 (Ultrasensitive assay) in October 2004; Abbott LCx HIV-1 assay (January 2005–May 2005); Abbott Real-Time HIV-1
assay (May 2005 onwards). Antiretroviral agents included in therapeutic drug monitoring in 2008 were as follows: lamivudine, efavirenz, atazanavir,
amprenavir, indinavir, nelﬁnavir, lopinavir, ritonavir, saquinavir, darunavir, tipranavir. (C) Susceptibility of the patient’s CD4+ T cells to superinfection
with clade (B) and (C) virus isolates and to induction of endogenous HIV-1: frequencies of p24 Ag+ CD4+ T cells after in vitro activation of CD8-depleted
peripheral blood mononuclear cells (PBMCs), followed by superinfection and culture for 6 days, or culture without superinfection (autologous virus) for up to
11 days. (D) Inhibition of replication of superinfecting or autologous viruses by patient’s CD8+ T cells after 6 days’ coculture at CD8/CD4 cell ratios indicated.
(E) Responses to individual clade C consensus Gag peptides identiﬁed in the peptide matrix assays were conﬁrmed by interferon (IFN)-γ enzyme-linked
immunospot (ELISPOT) assays with unfractionated PBMCs. Negative control values have been subtracted. Some of these peptides overlapped “beneﬁcial”
regions within clade B and C Gag that were previously associated with virological control—shown in bold [9]. (F) CD4+ T-cell responses to peptides rep-
resenting beneﬁcial regions within clade B/C Gag (listed in Supplementary Table 1) were determined in IFN-γ ELISPOT assays with CD8-depleted PBMCs.
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DISCUSSION
This case shows that long-term control of viremia and normal-
ization of immune parameters may follow discontinuation of
prolonged ART initiated at PHI, even in the context of persis-
tent viremia of nearly 5 log10 HIV-1 c/mL during initial ART
and the absence of favorable HLA alleles. Such features would
typically preclude long-term nonprogressor status [10].
Salgado et al and Sáez-Cirión et al have reported post-ART
virological control after treatment during PHI, despite initial vi-
remia of up to 7 log10 c/mL. The majority of these subjects had
an inducible viral reservoir, indicating that they were infected
with replication-competent viruses [2, 3]. We conﬁrmed that
our patient’s CD4+ T cells were susceptible to superinfection
with R5- and X4-tropic viruses, with similar frequencies of in-
fected cells to those we have observed following in vitro infection
of healthy donor PBMCs [11]. Furthermore, we were able to
detect outgrowth of endogenous HIV-1 in CD4+ T cells after
in vitro activation, albeit at a low level, indicating a persistent in-
ducible reservoir. Although posttreatment controllers thus show
some virological similarities with patients with spontaneous elite
control of HIV-1, an intriguing difference is the lower activation
status in the former [12]. Our patient also showed posttreatment
control of immune activation: the frequency of CD38+ CD8+
T cells has remained within normal limits throughout follow up.
With regard to HIV-speciﬁc immune responses, this case is
distinct from previously described posttreatment controllers [2,
3]. CD8+ T-cell inhibition of both heterologous and autologous
HIV-1 replication was detected at a low CD8+/CD4+ cell ratio.
Although these responses were less potent than was observed in
HIV controllers (median 85%, n = 20) [8, 13], they nevertheless
surpassed that of chronic ART-treated individuals who were vi-
rologically suppressed for ≥1 year (median 24%, n = 42; our un-
published observations). This result suggests that our patient’s
CD8+ T-cell antiviral responses were likely to be a contributing
factor to her virological control, rather than a consequence of it.
The preserved and broad HIV-1-speciﬁc CD4+ T-cell responses
observed in this patient are also particularly surprising when
taking into account the profound CD4+ T-cell depletion ob-
served before ART initiation. It is noteworthy that this patient
had detectable CD4+ T cell responses (polyfunctional and
proliferative) in 2004 and 2008 (Supplementary Figures 2–4).
Furthermore, we were able to show that CD4+ T cells were
targeted to multiple regions of vulnerability within Gag. Such
responses have been associated with spontaneous control of
viremia [9, 14]. It is not known whether this association is me-
diated by direct cytolytic mechanisms or indirectly, through
provision of effective help to CD8+ T cells. This deserves further
exploration. We also considered the possibility that humoral re-
sponses contributed to this patient’s posttreatment control, be-
cause broadly neutralizing antibodies may play a role in
controlling viremia in rare cases [15]. However, we found
only low levels of neutralizing antibodies to heterologous
virus in this case, when tested during the early period of avire-
mia in 2006–2007 (data not shown).
CONCLUSIONS
In conclusion, we have identiﬁed an atypical case of posttreat-
ment control, which may have been achieved through very early
ART during PHI combined with effective cell-mediated im-
mune responses. Our data suggest that strategies aiming to in-
duce such immune responses during early ART might inﬂuence
posttreatment virological control.
Supplementary Material
Supplementary material is available online at Open Forum Infectious
Diseases (http://OpenForumInfectiousDiseases.oxfordjournals.org/).
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